Literature DB >> 19684405

Effectiveness of combination use of antibiotic-loaded PerOssal with spinal surgery in patients with spondylodiscitis.

Dietrich von Stechow1, M A Rauschmann.   

Abstract

Degradable composites of calcium sulphate and nanoparticulate hydroxyapatite (PerOssal) have shown promising results in vitro. Here we investigated the handling, efficacy and compatibility of PerOssal when loaded with gentamicin or vancomycin in 19 patients with spondylodiscitis in vivo. So far, 12 patients who were followed up over at least 1 year have shown a normalization of the infection parameters, no more bone loss in the affected regions and a bony fusion after 3-6 months postoperatively. No revision surgery was related to the use of PerOssal. Locally there were no signs of an ongoing infection. This study demonstrates encouraging results regarding handling, resorption, biocompatibility and antibiotic release using PerOssal pellets in vivo. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19684405     DOI: 10.1159/000233525

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  11 in total

1.  [Systemic and local antibiotic therapy of conservative and operative treatment of spondylodiscitis].

Authors:  C Fleege; T A Wichelhaus; M Rauschmann
Journal:  Orthopade       Date:  2012-09       Impact factor: 1.087

2.  [Local fixation of antibiotics by fibrin spray : In bone defects with soft tissue involvement].

Authors:  Maren Janko; Christoph Nau; Ingo Marzi; Johannes Frank
Journal:  Chirurg       Date:  2017-02       Impact factor: 0.955

3.  Hydroxyapatite/silver electrospun fibers for anti-infection and osteoinduction.

Authors:  Feifei Liu; Xiaohui Wang; Tongtong Chen; Naiyin Zhang; Qin Wei; Juling Tian; Yingbo Wang; Chuang Ma; Yong Lu
Journal:  J Adv Res       Date:  2019-10-09       Impact factor: 10.479

4.  Pharmacokinetic properties and systemic safety of vancomycin-impregnated cancellous bone grafts in the treatment of spondylodiscitis.

Authors:  Konstantinos Anagnostakos; Katrin Koch
Journal:  Biomed Res Int       Date:  2013-07-17       Impact factor: 3.411

Review 5.  Clinical Application of Antimicrobial Bone Graft Substitute in Osteomyelitis Treatment: A Systematic Review of Different Bone Graft Substitutes Available in Clinical Treatment of Osteomyelitis.

Authors:  T A G van Vugt; J Geurts; J J Arts
Journal:  Biomed Res Int       Date:  2016-01-21       Impact factor: 3.411

6.  Clinical results of a lamina with spinous process and an iliac graft as bone grafts in the surgical treatment of single-segment lumbar pyogenic spondylodiscitis: a retrospective cohort study.

Authors:  Ke Tang; Weiyang Zhong; Xiaolin Wang; Xiaoji Luo; Zhengxue Quan
Journal:  BMC Surg       Date:  2022-02-11       Impact factor: 2.102

7.  Vancomycin-impregnated calcium sulfate beads compared with vancomycin powder in adult spinal deformity patients undergoing thoracolumbar fusion.

Authors:  Grace Xiong; Harold Fogel; Daniel Tobert; Thomas Cha; Joseph Schwab; Christopher Bono; Stuart Hershman
Journal:  N Am Spine Soc J       Date:  2020-12-31

8.  Divergent resorbability and effects on osteoclast formation of commonly used bone substitutes in a human in vitro-assay.

Authors:  Johannes Keller; Silja Brink; Björn Busse; Arndt F Schilling; Thorsten Schinke; Michael Amling; Tobias Lange
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

9.  First report on treating spontaneous infectious spondylodiscitis of lumbar spine with posterior debridement, posterior instrumentation and an injectable calcium sulfate/hydroxyapatite composite eluting gentamicin: a case report.

Authors:  Richard Bostelmann; Hans Jakob Steiger; Armin O Scholz
Journal:  J Med Case Rep       Date:  2016-12-12

Review 10.  Use of contemporary biomaterials in chronic osteomyelitis treatment: Clinical lessons learned and literature review.

Authors:  Jan A P Geurts; Tom A G van Vugt; Jacobus J C Arts
Journal:  J Orthop Res       Date:  2020-11-04       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.